LXRX - Lexicon Pharmaceuticals Inc Stock Price, Fair Value and News

$1.41+0.07 (+5.22%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

LXRX Price Action

Last 7 days

-1.4%

Last 30 days

3.7%

Last 90 days

31.8%

Trailing 12 Months

98.6%

LXRX RSI Chart

LXRX Valuation

Market Cap

512.4M

Price/Earnings (Trailing)

-7.47

Price/Sales (Trailing)

16.6

EV/EBITDA

-6.38

Price/Free Cashflow

-7.06

LXRX Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

LXRX Fundamentals

LXRX Revenue

Revenue (TTM)

31.1M

Rev. Growth (Yr)

1.7K%

Rev. Growth (Qtr)

4.17%

LXRX Earnings

Earnings (TTM)

-68.6M

Earnings Growth (Yr)

80.3%

Earnings Growth (Qtr)

-492.65%

LXRX Profitability

EBT Margin

-282.35%

Return on Equity

-57.07%

Return on Assets

-33.3%

Free Cashflow Yield

-14.17%

LXRX Investor Care

Shares Dilution (1Y)

0.53%

Diluted EPS (TTM)

-0.18

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2025	0	0	0	0
2024	2.3M	3.6M	5.2M	31.1M
2023	0	588.0K	516.0K	1.2M
2021	18.1M	12.1M	6.2M	298.0K
2020	320.9M	320.3M	32.5M	24.0M
2019	47.1M	42.9M	330.4M	322.1M
2018	99.1M	100.8M	80.1M	63.2M
2017	88.8M	80.8M	80.8M	91.7M
2016	140.7M	160.4M	187.6M	83.3M
2015	24.4M	24.1M	24.2M	130.0M
2014	2.1M	2.6M	2.8M	22.9M
2013	1.1M	1.2M	1.0M	2.2M
2012	1.6M	1.2M	1.2M	1.1M
2011	3.9M	3.2M	2.8M	1.8M
2010	0	8.8M	6.8M	4.9M
2009	0	0	0	10.7M

Get all data in R, Python etc through our Historical Stock Data APIs

About Lexicon Pharmaceuticals Inc

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.

CEO	Mr. Lonnel Coats
WEBSITE	lexpharma.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	135

Lexicon Pharmaceuticals Inc Frequently Asked Questions

What is the ticker symbol for Lexicon Pharmaceuticals Inc? What does LXRX stand for in stocks?

LXRX is the stock ticker symbol of Lexicon Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Lexicon Pharmaceuticals Inc (LXRX)?

As of Wed Dec 03 2025, market cap of Lexicon Pharmaceuticals Inc is 512.39 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of LXRX stock?

You can check LXRX's fair value in chart for subscribers.

Is Lexicon Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether LXRX is over valued or under valued. Whether Lexicon Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Lexicon Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for LXRX.

What is Lexicon Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Dec 03 2025, LXRX's PE ratio (Price to Earnings) is -7.47 and Price to Sales (PS) ratio is 16.6. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. LXRX PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Lexicon Pharmaceuticals Inc's stock?

In the past 10 years, Lexicon Pharmaceuticals Inc has provided -0.202 (multiply by 100 for percentage) rate of return.